
Please visit answersincme.com/PNQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rachel Goodwin, MSc, MD, FRCPC; and Vincent Tam, MD. In this activity, experts in colorectal cancer and biliary tract cancer discuss first-line immunotherapy considerations. Upon completion of this activity, participants should be better able to: Evaluate the clinical profiles of first-line immunotherapy-based regimens for the treatment of patients with advanced colorectal cancer (CRC); Formulate strategies to individualize first-line immunotherapy-based regimens for patients with advanced CRC; Describe the clinical evidence on first-line immunotherapy-based regimens for patients with advanced biliary tract cancer (BTC); and Apply patient-, drug-, and disease-specific considerations to optimize first-line immunotherapy-based regimens for patients with advanced BTC.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Clinical Pearls for Subcutaneous Delivery: Optimizing Anti-CD38 Use in Multiple Myeloma

Expanding the Use of HER2-Directed ADCs Into Early-Stage Breast Cancer: Multidisciplinary Conversations on (Neo)Adjuvant Care

KIT D816V in Focus: Optimizing Diagnosis and TKI Therapy in Advanced Systemic Mastocytosis

Cracking the Code of KRAS-Mutant NSCLC: Evidence for Emerging Therapies in First-Line Settings
Free AI-powered recaps of CME in Minutes: Education in Oncology & Hematology and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.